Kamada Announces Special Cash Dividend
Kamada Ltd. (NASDAQ: KMDA), a global biopharmaceutical company renowned for its innovative products tailored for rare and serious conditions, has made an impactful announcement. The company declared a special cash dividend of $0.20 per share, a move that reflects its robust financial performance and commitment to enhancing shareholder value. This significant dividend, approximately amounting to $11.5 million, is set to be payable to shareholders on a specified date.
Details of the Cash Dividend
The announcement comes as Kamada celebrates its first dividend since the company's inception. Amir London, the Chief Executive Officer of Kamada, expressed enthusiasm over the company’s strong financial results and liquidity this past year, stating, "We are pleased to announce a special cash dividend to our shareholders for the first time since Kamada's establishment." This demonstrates the confidence the board has in the company’s sustained growth and profitability.
Financial Health and Growth Strategy
Kamada has strategically positioned itself for continued growth. The conclusion of 2024 saw the company reporting strong financial outcomes, which has simultaneously boosted its cash reserves. London elaborated on the company’s growth pillars, emphasizing the focus on organic commercial growth, business development opportunities, and advancing their cutting-edge lead product, Inhaled AAT. Kamada is at the forefront of the plasma-derived therapy sector, determined to propel its innovative solutions for treating serious medical conditions.
Tax Implications of the Dividend
As per Israeli law, Kamada will impose a withholding tax on the declared dividend. In preparation for this, the company has sought a ruling from the Israel Tax Authority concerning tax withholdings applicable to non-Israeli shareholders. Further details regarding this ruling will be shared upon receipt. This approach aims to maintain transparency while ensuring compliance with regional financial regulations.
About Kamada Ltd.
Kamada Ltd. is dedicated to delivering specialized biopharmaceutical products that cater to the needs of patients with rare conditions. The company’s offerings include several FDA-approved plasma-derived treatments, such as KEDRAB®, CYTOGAM®, and GLASSIA®. Kamada is also actively involved in expanding its plasma collection operations, currently operating centers in Texas and planning to open additional centers to meet the increasing demand for plasma products. This strategic expansion is seen as vital for driving revenue and fulfilling its commitment to healthcare advancements.
Continued Commitment to Innovation
Research and development are at the heart of Kamada’s operational strategy. The company intends to leverage its expertise in manufacturing and product development to introduce new medications that target critical unmet medical needs. The lead product candidate, Inhaled AAT, is also demonstrating promising progress in clinical trials, showcasing Kamada's dedication to pioneering therapeutic solutions.
Frequently Asked Questions
What is the cash dividend amount declared by Kamada?
Kamada has declared a special cash dividend of $0.20 per share.
When will the dividend be paid?
The cash dividend will be payable on a specified date, with shareholders of record qualified on another specific date.
What does this dividend signify for Kamada?
This dividend declaration reflects Kamada's strong financial health and its long-term commitment to generating shareholder value.
What are the core growth strategies of Kamada?
Kamada focuses on organic growth, business development, plasma collection expansion, and advancing its product candidates in the biopharmaceutical market.
Where are Kamada's plasma collection centers located?
Kamada currently operates two plasma collection centers in Texas and plans to open a third center soon.
